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For the identiﬁcation of genes associated with smoking initiation and current smoking, genome-wide association analyses were carried
out in 3497 subjects. Signiﬁcant genes that replicated in three independent samples (n¼ 405, 5810, and 1648) were visualized into a bio-
logically meaningful network showing cellular location and direct interaction of their proteins. Several interesting groups of proteins
stood out, including glutamate receptors (e.g., GRIN2B, GRIN2A, GRIK2, GRM8), proteins involved in tyrosine kinase receptor signaling
(e.g., NTRK2, GRB14), transporters (e.g., SLC1A2, SLC9A9) and cell-adhesion molecules (e.g., CDH23). We conclude that a network-
based genome-wide association approach can identify genes inﬂuencing smoking behavior.Introduction
Large-scale population-based twin and family studies have
established that genetic factors contribute to individual
differences in multiple aspects of smoking behavior.1
According to the World Health Organization, smoking-
related diseases constitute the second leading cause of
death in the world (see Web Resources). Numerous studies
have shown that smoking initiation (SI) and current
smoking (CS) behavior are heritable traits.1–3 A meta-anal-
ysis estimated a heritability of 37% and 55% (for males and
females, respectively) for SI and a heritability of 59% and
46% (for males and females, respectively) for CS.1 Both SI
and CS signiﬁcantly correlated with other dimensions of
smoking behavior, such as quantity of cigarettes smoked
and nicotine dependence—as measured, for example,
with the Fagerstro¨m Test for Nicotine Dependence.2–5
The correlation of nicotine dependence with SI and CS is
attributable to genetic correlations, but the genetic overlap
is only partial.2,6,7 Identiﬁcation of genes underlying the
vulnerability to smoking might help identify more effec-The Amertive prevention strategies and thus diminish smoking-
related morbidity.
Linkage studies of smoking behavior identiﬁed thirteen
chromosomal regions with suggestive or signiﬁcant signals
in at least two independent samples.8 Studies of candidate
genes, which generally tend to lie outside these linkage
peaks, have failed to provide replicated evidence for
a contribution of these genes to smoking behavior.9,10
This might have multiple reasons, including inappropriate
choice of candidate genes or small sample sizes combined
with the probable small contribution of individual loci to
complex behaviors such as smoking.10 Genome-wide asso-
ciation (GWA) studies, followed by replication in multiple
data sets, offer the prospect of overcoming these shortcom-
ings.11,12 There have been GWA studies for nicotine depen-
dence,13,14 smoking cessation,15 number of cigarettes
smoked per day,16,17 and addiction vulnerability18,19 but
not for SI or CS. Although dimensions of smoking behavior
are genetically correlated, the overlap is only partial.
A major challenge of the GWA approach is that because
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genotype-phenotype tests, it tends to focus exclusively on
individual genes and/or regions that have the strongest
statistical evidence for association. However, individuals
can be at risk for smoking through multiple genetic vari-
ants acting on different proteins in the same functional
network.
When the evidence for a signiﬁcant contribution of
genetic variation in a region comes only from a subset of
individuals, the signal strength for a single gene might
be small, even in large samples. These effects are likely to
be pruned out in GWA studies by the need to adjust for
multiple testing.9 Pathway-based approaches have been
suggested as an alternative strategy to GWA data. These
approaches can yield biological insights that are not
obtained by the focus on individual genes and/or regions
that have the strongest statistical evidence for associa-
tion.20 A pathway-based approach identiﬁes whether
single-nucleotide polymorphisms (SNPs) in genes prede-
ﬁned to belong in a certain pathway showmore signiﬁcant
association results than expected by chance. It can
conﬁrm hypothesized causal pathways and disease mech-
anisms a priori but can also detect novel pathways and
mechanisms.
In general, the grouping of genes in pathway-based
approaches is based on existing knowledge of gene func-
tion. A potential disadvantage of this approach is that prior
knowledge in correctly assigning genes to a certain
pathway is crucial. Moreover, genes may have diverse func-
tions, and this might not always be reﬂected in pathway
assignment. In this paper, we aim to identify a biologically
meaningful network of genes involved in SI and CS by
using a novel variant of a pathway-based approach in
which the grouping of genes is less restricted. Our method
uses the growing knowledge of gene structure, biological
function, and protein localization in the cell, along with
established protein-protein interactions. In an initial
discovery sample (n ¼ 3497 subjects), a GWA approach
was used in selecting genes with one or more SNPs that
were associated with SI (ever smoked versus never smoked)
or CS (current smoker versus never smoked or ex-smoker)
at a liberal p value threshold of 5 3 103. The selected
genes were then examined in three independent replica-
tion samples (Leiden study n ¼ 405, Rotterdam study
n ¼ 5810, and GenomEUtwin project n ¼ 1648). Genes
with SNPs that were associated with SI or CS at a p value
threshold of 5 3 103 were considered to be replicated.
The proteins encoded by these replicated genes were visu-
alized in a biologically meaningful network of functional
groups, in which information from a manually curated
expert database (Ingenuity Systems) is used to show
cellular location and direct interactions between proteins.
The most interesting groups of proteins thus identiﬁed
include a group of glutamate receptors (e.g., GRIN2B,
GRIN2A, GRIK2, GRM8), proteins involved in tyrosine
kinase receptor signaling (e.g., NTRK2, GRB14), trans-
porters (e.g., SLC1A2, SLC9A9), and cell-adhesion mole-
cules (e.g., CDH23).368 The American Journal of Human Genetics 84, 367–379, MarchMaterial and Methods
Description of the Discovery Sample
The two parent projects that supplied data for the discovery
sample are large-scale longitudinal studies: the Netherlands Study
of Depression and Anxiety (NESDA)21 and the Netherlands Twin
Registry (NTR).22 NESDA and NTR studies were approved by the
Central Ethics Committee on Research Involving Human Subjects
of the VU University Medical Center, Amsterdam (IRB number
IRB-2991 under Federalwide Assurance 3703; IRB/institute codes,
NESDA 03-183; NTR 03-180).
The sample consisted of 1777 participants from the NTR and
1763 participants from the NESDA. The mean age of the partici-
pants was 43.8 years (SD 13.4), and 65.7% of the sample was
female. For participants of the NTR, longitudinal-survey data
from seven waves of data collection (1991–2004) were used in
determining whether a participant ever smoked. CS behavior
was assessed when DNA samples were collected (2004–2007). For
participants from NESDA, data on SI and CS were collected during
a clinical interview between 2004 and 2007.21 Genome-wide anal-
yses were carried out for two phenotypes: SI (ever smoked versus
never smoked) and CS (current smokers versus nonsmokers).
The nonsmokers group included both ex-smokers and never
smokers.
Genotyping of the Discovery Sample
The genotypic data used in the discovery sample are part of one of
the six initial Genetic Association Information Network (GAIN)
studies sponsored by the Foundation for the National Institutes
of Health (NIH).23 Sampling, data-collection characteristics, and
genotype-cleaning procedures of the GAIN-major depressive
disorder (MDD) study have been described in detail elsewhere.24,25
In short, individual genotyping was conducted by Perlegen
Sciences (Mountain View, CA, USA) with the use of a set of four
proprietary, high-density oligonucleotide arrays. The SNPs on
these arrays were selected for tagging of common variation in
the HapMap European and Asian panels. Of the 3820 Dutch
samples sent to Perlegen, genotypes were delivered for 3761
samples (98.5%), of which 3540 subjects passed quality controls25
and were available in the ﬁnal analysis data set including 1738
MDD cases and 1802 controls (96.9%).
Precautions against population stratiﬁcation are detailed by
Sullivan et al.25 In brief, we removed subjects with non-European
descent on the basis of a principal-components analysis.25 A strat-
iﬁed Cochran-Mantel-Haenszel test was used as a complementary
approach. The genomic inﬂation factors (lambda) for SI and CS in
the ﬁnal sample were close to 1 (1.008 and 1.009, respectively),
suggesting that the observed associations are unlikely to be the
result of population stratiﬁcation.
The SNP quality-control process is described in detail in the
Supplementary Methods of Sullivan et al.25 In brief, the unﬁltered
data set obtained from dbGaP, a database of genome-wide associa-
tion studies, contained 599,156 unique SNPs. For inclusion in the
ﬁnal analysis data set, SNPs were required not to have any of the
following features: grossmapping problem,R 2 genotype disagree-
ments in 40 duplicated samples,R 2Mendelian inheritance errors
in 38 complete trio samples, minor allele frequency < 0.01,
or > 0.05 missing genotypes in either cases or controls. A Hardy-
Weinbergﬁlterwasnotused,because a lackofﬁt toHardy-Weinberg
expectations can occur for valid reasons (e.g., a true association)
and over 96% of SNPs not in Hardy-Weinberg equilibrium were13, 2009
Table 1. Description of the Samples with Genome-wide Association Data and Smoking Phenotypes
N Subjects Mean Age (SD) % Female % Ever Smoked % Current Smoker
Discovery sample (The Netherlands) 3497 43.8 (13.4) 65 64.0 29.9
GenomEUtwin (Europe and Australia) 1648 48.0 (15.1) 100 49.5 24.8
Rotterdam (The Netherlands) 5810 69.4 (9.1) 59 63 23.0
Leiden (The Netherlands) 405 59.6 (7.2) 57 72 13.3removed by other ﬁlters. A total of 427,037 SNPs on chr1 to chr22
met these criteria and were included in the ﬁnal association anal-
yses with the smoking phenotypes.
Replication Samples
Replication was sought in full GWA data obtained in three inde-
pendent replication samples. For all samples, the number of partic-
ipants, the mean age, the percentage of female participants, the
percentage of participants with the SI phenotype, and the
percentage of participants with the CS phenotype are shown in
Table 1. Data on SI and CS were available for all three replication
samples. None of the replication-sample participants were selected
on the basis of smoking behavior or psychiatric disorder.
Rotterdam Study
The Rotterdam Study is a prospective cohort study that started in
1990 in Ommoord, a suburb of Rotterdam, among 10,994 men
and women aged 55 and over. The main objective of the Rotterdam
Study is to investigate the prevalence, incidence, and risk factors
for cardiovascular, neurological, locomotor, and ophthalmologic
diseases in the elderly. Baseline measurements were obtained
between 1990 and 1993. All participants were subsequently exam-
inedinfollow-upexaminationroundsevery2–3years. For this study,
data from 6000 participants with GWA information were available.
Leiden Study
Families with at least two long-living siblings were included in the
Leiden Longevity Study.26 The offspring of the long-living sib pairs
and their partners were also enrolled. For this study, we used data
from 405 (unrelated) partners.
GenomEUtwin Study
This is an unselected population-based cohort of twins from Euro-
pean countries and Australia.27 A subsample of twins for whom
DNA samples and lipid data were available were genotyped for
GWA studies. The subsample consisted of data from Finland (n ¼
142), Sweden (n ¼ 302), Denmark (n ¼ 142), Australia (n ¼ 472),
the United Kingdom (n ¼ 341), and The Netherlands (n ¼ 249).
All subjects were monozygotic female twins. When phenotype
data of both members of a twin pair were available, the subject
was categorized as positive for CS or SI if at least one of the twins
was a current smoker or initiated smoking.
The GenomEUtwin samples were genotyped with the Inﬁnium
II assay on the HumanHap300-Duo Genotyping BeadChips (Illu-
mina, San Diego, CA, USA). The Rotterdam and Leiden samples
were genotyped with the Affymetrix 500K SNP chip.
Statistical Power
Quanto28 was used for approximating statistical power for a log-
additive genetic model with, the following parameter values for
CS: two-tailed a ¼ 1 3 107 (0.05 / 427,037), 1060 cases and
2458 controls, population risk of 0.25. For statistical power of
0.80 (b ¼ 0.20), the minimum detectable genotypic relative risks
are 1.67 / 1.44 / 1.39 for minor allele frequencies of 0.10 / 0.25 /
0.40. For SI, with 2272 cases and 1227 controls and a populationThe Amerisk of 0.50, the minimum detectable genotypic relative risks
are 1.70 / 1.44 / 1.38 for the minor allele frequencies of 0.10 /
0.25 / 0.40. When a ¼ 0.005, the minimum detectable genotypic
relative risks are 1.36 / 1.25 / 1.22 for CS and 1.37 / 1.24 / 1.21
for SI.
The minimum detectable genotypic relative risk in the replica-
tion samples was estimated for two-tailed a ¼ 5.36 3 105 (0.05 /
932) and a statistical power of 0.80 (b¼ 0.20).With the sameminor
allele frequencies of 0.10 / 0.25 / 0.40, the minimum detectable
genotypic relative risks for SI are 1.79 / 1.49 / 1.43 for GenomEUt-
win data, 1.38 / 1.25 / 1.21 for Rotterdam Study data, and 4.39 /
2.58 / 2.27 for Leiden Longevity Study data. For CS, the estimates
are 1.87 / 1.57 / 1.50 for GenomEUtwin, 1.42 / 1.28 / 1.25 for Rot-
terdam, and 4.62 / 3.12 / 2.88 for Leiden. For a ¼ 0.005, the
minimum detectable genotypic relative risks for SI are 1.54 / 1.35 /
1.30 for GenomEUtwin, 1.27 / 1.18 / 1.16 for Rotterdam, and 2.84 /
1.99 / 1.83 for Leiden, and for CS, they are 1.61 / 1.40 / 1.36 for
GenomEUtwin, 1.30 / 1.21 / 1.18 for Rotterdam, and 3.14 / 2.32 /
2.18 for Leiden.
Statistical Analyses, Software, and Bioinformatics
In the discovery sample, the GenomEUtwin sample, and the
sample from the Leiden study, GWA was carried out in Plink29
with the use of a logistic-regression model with a dependent vari-
able (ever smoked: yes/no; currently smoking: yes/no) and the
covariates of age and sex (sex not used as a covariate for the
GenomEUtwin sample, because the sample consisted of women
only). For the Rotterdam sample, GWA was carried out through
regressing smoking status on the estimated allele dosage with
the use of a logistic model, with the covariates of age and sex, in
ProbABEL,28 with data of measured and imputed SNPs data.
Genetic imputations were performed with the use of the
maximum-likelihood method, as implemented in the MACH soft-
ware,30 with the HapMap release 22 CEU data used as the reference
population.
Permutation tests on the gene level were performed by use of
the –set-test option in Plink (–mperm 1000,–set-max 1,–set-
p 0.01,–set-r2 ¼ 0.5) in the discovery sample. It was not possible
to include covariates in the permutation test. Some SNPs that
reached the signiﬁcance threshold in the GWA with covariates
did not reach the signiﬁcance threshold in the permutation test
without covariates, and as a consequence, the empirical p value
was not calculated for those genes.
SPSS and Haploview were used for data management, statistical
analyses, and graphics. SNP annotations were created with the use
of the ENSEMBL database.
Ingenuity Pathway Analysis (Ingenuity Systems, release IPA 6.0)
was used for visualizing interactions between proteins (encoding
the selected genes) in a network. The Ingenuity database contains
a large amount of information about structure, biological func-
tion, and subcellular localization of the proteins, as well as infor-
mation about direct protein-protein interactions. In the graphical
representation, proteins are represented as nodes. Nodes arerican Journal of Human Genetics 84, 367–379, March 13, 2009 369
displayed as various shapes that represent the functional class of
the gene product. Nodes were manually reorganized with the
use of the ‘‘pathway designer’’ tool for the grouping of proteins
with related structure or function. The biological relationship
between two nodes is represented as a line (edge). All lines are
supported by at least one reference from the literature, from
a textbook, or from canonical information stored in the Ingenuity
Pathways Knowledge Base.
Results
GWAS in Discovery Sample
The discovery sample consisted of 3497 Dutch subjects
from the NTR or NESDA study.21,22 At the time of DNA
sampling, 64% had ever smoked and 46% were current
smokers. Descriptive data for the discovery sample and
the replication samples are presented in Table 1.
In the discovery sample, GWA analyses were performed
for 427,037 autosomal SNPs with the use of logistic regres-
sion adjusted for sex and age. Tables 2 and 3 show the top
SNPs for SI and CS. SNP rs4423615 (located in GRB14) is
associated with both SI and CS (p ¼ 5.3 3 105 and p ¼
6.83 105, respectively). For SI, the smallest p value is 4.33
106 (rs10794595; chromosome10). This SNP is not located
in a gene and is not in linkage disequilibrium (LD) (>0.50)
with any other SNP. For CS the smallest p value is
8.8x107 (rs6484176; chromosome 11). This SNP is also
not located in a gene but is in LD (>0.50) with two other
SNPs that both show a signiﬁcant association with CS
(rs1532289,p¼3.63106 andrs10219359,p¼5.73104).
The columnN_LD in Tables 2 and 3 shows the number of
SNPs that are in LD with the signiﬁcant index SNP. Several
clusters of SNPs with low p values (within a physical
distance of 250 kb from the index SNP) are found. For
example, rs8009082 is associated with SI (p ¼ 5 3 105)
and is in LD with six other SNPs with p values < 0.05 for
SI (see Table 2). All SNPs are located in the TRIM9 gene
(intronic). Another example shows two SNP clusters on
chromosome 7, associated with CS: rs6972429 (41,668,
0820 bp, p ¼ 8.3 3 105) is in LD with six other SNP (all
p values < 0.05 with CS), and a nearby SNP, rs29684
(41,627,892, p ¼ 8.7 3 105), is in LD with four other
SNPs (all p values < 0.05 with CS; see Table 3).
The maximum effect size for the top SNPs is an odds
ratio of 1.78 for rs9824246 for SI and 2.12 for rs6661946
and rs2404646 for CS. Given the high heritability of SI
and CS, these effect sizes are consistent with multiple
genes of modest effect contributing to smoking behavior.
Selection of Genes for Network Analysis
First, we selected all SNPs with p values < 0.005 in the
discovery sample. In total, 4213 SNPs passed this ﬁlter;
1931 for SI, 2065 for CS, and 217 for both phenotypes.
For SI and CS, 1195 and 1325 SNPs, respectively, were not
located within a gene. The remaining SNPs were located
in 1041different genes.Whenpredicted or uncharacterized
genes (like C10orf11, NP_001018001.1, etc.) were deleted370 The American Journal of Human Genetics 84, 367–379, March 1from the set, 932 genes were left: 386 genes for SI, 407 for
CS, and 139 associated with both phenotypes.
Examination of these genes in the replication samples
showed that almost half (48%) had one or more SNPs
with p values < 0.005 in one or more of the replication
samples.
We selected genes that were replicated at least twice in
the replication samples (n ¼ 193) or were replicated only
once but had a structurally related family member (GO
classiﬁcation) that was replicated at least twice (n ¼ 108)
(see Supplemental Data, available online). The entire
gene-selection procedure, from discovery set to the ﬁnal
set of genes for the network analysis, is shown in Figure 1.
The ﬁnal set of selected genes (n ¼ 302) was entered into
the Ingenuity database (release IPA 6.0), and a connectivity
diagram was built on the basis of direct interactions only
(Figure 2). Geneswere then grouped, through the ‘‘pathway
designer’’ function, on the basis of related protein structure
and/or function.
Permutation Test
Larger genes might contain more SNPs and therefore be
more likely to be selected because of a signiﬁcant p value.20
To adjust for gene size, we carried out permutation tests at
the gene level (for the 316 selected genes), using the
permutation approach implemented in Plink.29 The
Supplemental Data includes the empirical p values based
on the discovery sample (for some genes, the empirical
p value could not be calculated; seeMaterial andMethods).
We retained all originally selected 302 genes in the connec-
tivity diagram (Figure 2), but grayscaled the genes that had
empirical p values above 0.05 when gene size was taken
into account.
Groups of Genes Associated with Smoking Initiation
and Current Smoking
Geneswhoseproteinshave similar biological functionhave
been grouped (see dotted boxes in Figure 2). In total,
12 genes involved in glutamate signaling had replicated
GWAS results, including three metabotropic glutamate
receptors and six ionotropic glutamate receptors. Those
nine glutamate receptor genes were each replicated
between one and four times in the replication samples,
and several genes were also associated with smoking or
addiction vulnerability in the literature. GRIN2B (MIM
138252), GRIK2 (MIM 138244), and GRM8 (MIM 601116),
showed p values < 104 (Tables 2 and 3) in the discovery
sample.
For thegenes involved in tyrosinekinase signaling,NTRK2
(MIM 600456) and GRB14 (MIM 601524) show the most
signiﬁcant associations with smoking behavior. NTRK2 is
associated with CS in the discovery sample (p ¼ 9.6 3
105) and in the Rotterdam sample (p ¼ 1.3 3 103).
GRB14 shows a noteworthy association for both SI (p ¼
5.23 105) andCS (p¼ 6.73 105) in the discovery sample.
It is replicated once in the Rotterdam sample (p ¼ 4.4 3
103 for SI).3, 2009
Table 2. Associations with p% 0.0001 in Genome-wide Analyses for Smoking Initiation in the Discovery Sample
Index SNPs with p Value < 0.0001 SNPs in LD with Index SNP Corresponding Genes
Chr
Index
SNP BP P OR
Minor
Allele N_ LD NS 01a 05b 001c 0001d
LD with
Index SNP &
p < 0.0001
Gene
Symbol Typee N_ SNPs
Location
of Index
SNP
2 rs4608580 98319575 7.905e-5 0.817 C 4 0 0 1 3 0 VWA3B O 1 Intronic
2 rs10865016 98447822 9.671e-6 1.356 A 1 0 0 0 1 0 CNGA3 IC 11 Intronic
2 rs787151 144489568 2.745e-5 1.304 A 2 0 0 1 1 0
2 rs4423615 165263737 5.290e-5 0.815 G 1 0 0 1 0 0 GRB14 O 18 Intronic
3 rs1599903 39930070 5.423e-5 1.238 C 5 0 0 2 3 0 MYRIP O 60 Intronic
3 rs9824246 73185415 9.951e-5 1.778 G 0 0 0 0 0 0 PPP4R2 O 7 Intronic
3 rs16860281 149478045 7.340e-6 0.672 C 1 0 0 0 1 0
4 rs7692181 64329760 7.625e-5 1.238 T 0 0 0 0 0 0
6 rs2395670 37190787 3.698e-5 1.257 A 1 0 0 0 1 0 FGD2 O 12 Intronic
6 rs9321013 125372620 4.946e-5 1.205 A 1 0 0 1 0 0 RNF217 E 1 Intronic
7 rs7805247 2883300 5.680e-5 0.763 C 1 0 0 1 0 0
7 rs6960379 63194667 6.579e-5 0.650 C 1 0 0 0 0 1 rs611097
7 rs2237781 126269001 4.017e-5 1.608 A 1 0 0 0 1 0 GRM8 GR 121 Intronic
7 rs4725563 139107440 2.798e-5 0.777 C 2 0 0 1 1 0 TBXAS1 E 38 Intronic
8 rs4509385 10217606 8.009e-5 0.818 A 1 0 0 0 1 0 MSRA O 144 Intronic
8 rs6997956 136553572 8.479e-6 1.257 A 1 0 0 0 1 0 KHDRBS3 O 13 Intronic
9 rs10121807 82366438 9.379e-5 0.729 G 0 0 0 0 0 0
9 rs10115383 100450087 7.691e-5 1.256 A 1 0 0 0 1 0
10 rs10999845 72910367 5.807e-5 1.320 G 1 0 0 0 1 0 CDH23 T 77 Intronic
10 rs3949478 97463204 3.203e-5 0.773 A 1 0 0 0 1 0 ENTPD1 O 10 Intronic
10 rs1856801 112382152 3.787e-5 1.414 T 0 0 0 0 0 0
10 rs7082195 112417439 4.374e-5 1.345 T 2 0 1 0 1 0 RBM20 O 1 Intronic
10 rs10794595 124871492 4.333e-6 0.786 T 0 0 0 0 0 0
11 rs17477949 12175779 3.733e-5 1.239 T 4 0 2 1 1 0 MICAL2 O 91 Intronic
11 rs12797615 85944331 4.278e-5 1.255 C 1 0 0 0 1 0 ME3 E 61 Intronic
11 rs737383 92304523 9.648e-5 0.818 C 0 0 0 0 0 0
11 rs4379857 132688814 9.737e-5 0.645 A 0 0 0 0 0 0 OPCML TM 345 Intronic
12 rs7313149 13719554 6.733e-5 0.779 C 1 0 0 0 0 1 rs2192972 GRIN2B IC 147 Intronic
12 rs4759802 129932057 7.443e-5 0.734 A 0 0 0 0 0 0
13 rs327127 28416900 2.283e-5 0.623 C 0 0 0 0 0 0
13 rs17295389 81213800 6.500e-5 0.738 A 3 0 0 1 2 0
14 rs8009082 50569094 5.011e-5 0.794 A 6 0 0 2 2 2 rs8005389,
rs11157796
TRIM9 O 64 Intronic
14 rs17252296 50650671 8.594e-5 0.796 C 2 0 0 1 1 0
14 rs8019291 92000917 8.087e-6 0.709 T 1 0 0 0 0 1 rs7154288 SLC24A4 T 49 Intronic
14 rs999986 94873609 7.324e-5 0.804 A 0 0 0 0 0 0
15 rs4774925 55391694 9.852e-5 1.237 T 1 0 0 1 0 0
16 rs12920919 9845481 1.000e-4 0.809 C 9 4 0 5 0 0
18 rs17739703 28777286 6.690e-5 1.473 C 0 0 0 0 0 0 C18orf34 O 17 Intronic
20 rs283277 52970231 1.582e-5 1.315 A 9 0 0 6 3 0
21 rs928302 42683153 1.230e-5 0.659 T 1 0 0 0 1 0 TMPRSS3 P 16 Coding
22 rs16982400 16272098 4.057e-5 1.355 C 0 0 0 0 0 0
N¼ 3497. A logistic-regression test was performed for smoking initiation (yes/no), with sex and age as covariates. Headings and abbreviations indicate the
following information: Chr, chromosome; Index SNP, SNPwith p value smaller than 0.0001;BP, base pair position of the index SNP; P, p value of the index SNP;
OR, odds ratio;N_LD, number of SNPs in LD (R 0.50) with the index SNP within a physical distance of 250 kb;NS, number of clumped SNPs that are not signif-
icant (p> 0.05); N_SNPs, number of SNPs measured in this gene; Gene symbol, name of the gene if the SNP is located in a gene or close to a gene (<50 kb).
Gene symbol: VWA3B denotes von Willebrand factor A domain-containing 3B; CNGA3 denotes Cyclic nucleotide-gated cation channel alpha 3; GRB14 denotes
Growth factor receptor-boundprotein 14;MYRIPdenotes Rab effectorMyRIP (Myosin-VIIa- andRab-interacting protein); PPP4R2 denotes Protein phosphatase
4, regulatory subunit 2; FGD2 denotes FYVE, RhoGEF and PH domain-containing protein 2; RNF217 denotes IBR domain-containing protein 1; GRM8 denotes
Metabotropic glutamate receptor 8 precursor; TBXAS1denotes Thromboxane-A synthase;MSRAdenotes Peptidemethionine sulfoxide reductase; CDH23denotes
Cadherin-23precursor; ENTPD1 denotes Ectonucleoside triphosphate diphosphohydrolase 1; RBM20denotes Novel protein (Fragment);MICAL2denotes Protein
MICAL-2; ME3 denotes NADP-dependent malic enzyme, mitochondrial precursor; OPCML denotes Opioid-binding protein/cell-adhesion molecule precursor;
GRIN2B denotes Glutamate [NMDA] receptor subunit epsilon-2 precursor; TRIM9 denotes Tripartite motif-containing protein 9; SLC24A4 denotes Sodium/
potassium/calcium exchanger 4 precursor; C18orf34 denotes Uncharacterized protein C18orf34; TMPRSS3 denotes Transmembrane protease, serine 3.
a Number of clumped SNPs 0.01 < p < 0.05.
b Number of clumped SNPs 0.001 < p < 0.05.
c Number of clumped SNPs 0.0001 < p < 0.001.
d Number of clumped SNPs p < 0.0001.
e Abbreviations are as follows: O, other; IC, ion channel; E, enzyme; GR, G protein coupled receptor; T, transporter; TM, transmembrane receptor; P, peptidase.The American Journal of Human Genetics 84, 367–379, March 13, 2009 371
Table 3. Associations with p% 0.0001 in Genome-wide Analyses for Current Smoking in the Discovery Sample
Chr
Index
SNP BP P OR
Minor
Allele N_LD NS 01a 05b 001c 0001d
LD with
Index SNP &
p < 0.0001
Gene
Symbol Typee N_SNP
Location
Index
SNP
1 rs1109374 65345518 7.972e-5 1.276 C 4 0 0 3 1 0 AK3L2 O 12 Intronic
1 rs12126638 212564091 9.556 e-5 1.277 C 4 0 1 1 2 0 USH2A O 155 Intronic
1 rs9424490 229328605 3.618 e-5 1.715 G 1 0 0 0 1 0
1 rs6661946 233049149 4.108 e-6 2.120 T 2 0 0 0 2 0 HEATR1 O 12 Coding
2 rs6709476 85355582 5.569 e-5 1.420 A 0 0 0 0 0 0 TCF7L1 TR 43 Intronic
2 rs13400652 123112107 5.724 e-5 0.836 T 0 0 0 0 0 0
2 rs4423615 165263737 6.777 e-5 0.811 G 1 1 0 0 0 0 GRB14 O 18 Intronic
2 rs17355446 179414747 1.381 e-5 2.120 A 1 0 0 0 1 0 TTN P 11 Coding
2 rs1549738 217944228 4.878 e-5 1.378 G 0 0 0 0 0 0
4 rs4833652 121832177 3.412 e-5 1.265 G 1 0 0 0 1 0
4 rs2404646 136443886 6.478 e-6 0.546 G 0 0 0 0 0 0
5 rs906071 10162385 9.375 e-5 1.255 C 1 0 0 1 0 0
5 rs17284420 82748776 1.0e-4 1.400 C 0 0 0 0 0 0
5 rs2964911 163656859 6.573 e-5 0.752 G 2 0 0 2 0 0
6 rs6570989 102064106 7.734 e-5 0.736 A 0 0 0 0 0 0 GRIK2 IO 114 Intronic
7 rs29684 41627892 8.741 e-5 1.046 C 4 0 0 4 0 0 rs17706620
7 rs6972429 41668082 8.319 e-5 1.246 C 6 0 0 3 2 1 rs12113526
7 rs6463462 47915434 7.957 e-5 0.810 G 5 0 0 0 5 0 UPP1 E 3 Intronic
8 rs2930357 3697068 2.082 e-5 0.766 C 1 0 0 1 0 0
9 rs4741746 2608969 2.984e-6 1.432 C 2 0 0 0 0 2 VLDLR T 9 50 upstr
9 rs10868236 84738250 9.642 e-5 0.748 G 1 0 0 1 0 0 NTRK2 K 70 Intronic
11 rs4758405 6281210 8.407e-6 1.266 A 0 0 0 0 0 0
11 rs10834489 24794377 2.5 e-5 0.798 T 1 0 1 0 0 0 LUZP2 139 Intronic
11 rs6484176 25744207 8.835e-7 1.355 C 2 0 0 0 1 1 rs1532289
12 rs4141130 1967977 1.51 e-5 0.785 C 0 0 0 0 0 0 DCP1B O 8 Intronic
12 rs983579 33036065 1.347 e-5 1.452 A 1 0 0 0 0 1 rs1113053
12 rs11109504 77258379 2.891 e-5 1.251 A 3 0 0 0 3 0
12 rs12302525 88228893 4.099 e-5 1.478 G 1 0 0 0 1 0
12 rs1036360 92955797 7.322e-6 0.766 G 0 0 0 0 0 0
13 rs263930 21136662 4.333 e-5 1.255 G 1 0 0 1 0 0
13 rs12874278 49833923 5.649 e-5 1.504 T 4 0 0 1 2 1 rs12864797
13 rs17371334 83930328 4.308 e-5 1.254 G 1 0 0 0 1 0
13 rs9554711 100074885 5.654 e-5 0.791 G 4 0 1 1 2 0 TMTC4 O 14 Intronic
13 rs2052383 104997529 3.853 e-5 0.747 G 0 0 0 0 0 0
15 rs3764213 20579108 9.313 e-5 0.741 G 1 0 1 0 0 0 NIPA2 O 5 Intronic
15 rs7173321 48709892 3.244 e-5 1.428 G 6 1 0 0 2 3 rs8042919,
rs12899074,
rs12898588
(PSL2)
TRPM7 K 12 Intronic
15 rs11636705 94406916 5.391 e-5 0.758 T 1 0 0 1 0 0
16 rs2911292 61138447 2.337 e-5 1.260 T 1 0 0 0 1 0
17 rs8082305 27130700 7.773 e-5 1.325 A 3 0 0 1 2 0
18 rs17665021 23476209 6.111 e-5 0.597 G 0 0 0 0 0 0
18 rs16944011 23546361 9.742 e-5 0.664 G 1 0 0 0 0 1 rs12606601
18 rs11082277 38304361 8.365 e-5 1.212 G 0 0 0 0 0 0
19 rs186715 6829136 2.503 e-5 0.797 G 0 0 0 0 0 0
22 rs6007413 43750853 4.804 e-5 0.728 G 2 0 1 0 0 1 rs10483226
22 rs16999684 47388171 3.129 e-5 0.766 C 2 0 0 0 1 1 rs5771932 FAM19A5 69 Intronic
22 rs5771934 47390743 9.028 e-5 1.278 T 0 0 0 0 0 0
N ¼ 3497. A logistic-regression test was performed for current smoking (yes/no), with sex and age as covariates. Headings and abbreviations indicate the
following information: Chr, chromosome; Index SNP, SNP with p value smaller than 0.0001; BP, base pair position of the index SNP; P, p value of the index
SNP; OR, odds ratio; N_LD, number of SNPs in LD (R 0.50) with the index SNP within a physical distance of 250 kb; NS, number of clumped SNPs that are
not significant (p> 0.05); N_SNPs, number of SNPs measured in this gene; Gene symbol, name of the gene if the SNP is located in a gene or close to a gene
(<50 kb).
Gene symbol: AK3L2 denotes Adenylate kinase isoenzyme 4, mitochondrial; USH2A denotes Usherin precursor (Usher syndrome type-2A protein); HEATR1
denotes HEAT repeat-containing protein 1; TCF7L1 denotes Transcription factor 7-like 1; GRB14 denotes Growth factor receptor-bound protein 14; TTN
denotes Titin isoform novex-3; GRIK2 denotes Glutamate receptor, ionotropic kainate 2 precursor (GluR-6); UPP1 denotes Uridine phosphorylase 1; VLDLR
denotes Very low-density lipoprotein receptor precursor (VLDL receptor); NTRK2 denotes Neurotrophic tyrosine kinase receptor type 2; LUZP2 denotes
Leucine zipper protein 2; DCP1B denotes mRNA-decapping enzyme 1B; TMTC4 denotes Transmembrane and TPR repeat-containing protein 4; NIPA2 denotes
Non-imprinted in Prader-Willi/Angelman syndrome region protein 2; TRPM7 denotes Transient receptor potential cation channel subfamily M member 7;
PSL2 denotes Signal peptide peptidase-like 2A; FAM19A5 denotes family with sequence similarity 19 (chemokine (C-C motif)-like), member A5.372 The American Journal of Human Genetics 84, 367–379, March 13, 2009
Figure 1. Selection Procedure for Connectivity Diagram Shown in Figure 2The next interesting group is that of the transporter
genes. Seven transporter genes passed the permutation
test (see colored symbols in Figure 2). The most signiﬁcant
ﬁnding within this group is found for SLC9A9 (MIM
608396), which shows an association with SI (in discovery
sample, p ¼ 6.1 3 104, and in all three replication
samples, p < 0.005) and with CS (in discovery sample,
p ¼ 1.2 3 104, and in the Rotterdam sample, p ¼ 7.5 3
104). Another gene worthy of note in this group is
SLC1A2 (MIM 600300), a glutamate transporter, which is
associated with CS (in discovery sample, p ¼ 3.0 3 103,
and in Rotterdam sample, p ¼ 3.6 3 103).
Another noticeable group of genes is formed by the
genes for the cell-adhesionmolecules. Themost signiﬁcant
ﬁnding within this group of genes isCDH23 (MIM 605516)
(p ¼ 5.8 3 105 for SI in the discovery sample and 3.2 3
103 for SI in the Rotterdam sample). Most other genesThe Amerin this group are grayscaled, indicating that they did not
pass the permutation test.
A small group is formed by two genes involved in the
opioid system: OPRM1 (MIM 600018) and OPCML (MIM
600632). The most signiﬁcant ﬁndings were the associa-
tions between OPCML and SI (p ¼ 9.7 3 105 in the
discovery sample, p¼ 1.93 103 in the Rotterdam sample,
p ¼ 4.1 3 103 in the GenomEutwin sample) and OPCML
and CS (p ¼ 1.3 3 103 in the discovery sample, p ¼ 1.1 3
103 in the Rotterdam sample, p ¼ 2.9 3 103 in the
GenomEutwin sample).
Discussion
Although smoking is often regarded as an environmental
‘‘lifestyle’’ trait, behavioral-genetics studies provide strong
evidence that genetic factors contribute substantially toa Number of clumped SNPs 0.01 < p < 0.05.
b Number of clumped SNPs 0.001 < p < 0.05.
c Number of clumped SNPs 0.0001 < p < 0.001.
d Number of clumped SNPs p < 0.0001.
e Abbreviations are as follows: O, other; IC, ion channel; E, enzyme; GR, G protein coupled receptor; T, transporter; TM, transmembrane receptor;
P, peptidase.ican Journal of Human Genetics 84, 367–379, March 13, 2009 373
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interindividual variation in all dimensions of smoking
behavior.
For detectionof these genetic factors, several linkage anal-
yses8 and association studies9,10 and, recently, some
GWAS13–19 were carried out. These previous GWAS have
only listed the 20–50 most signiﬁcant SNPs or genes, while
paying little attention to the remainder of the genes that
might contribute to the trait.20 The approach used here
builds upon this classic approach by ﬁrst selecting genes
of interest, on the basis of an (albeit liberal) signiﬁcance
threshold for SNPs within genes in the discovery sample,
then testing these for replication of the same or other
SNPs in these genes in novel samples. To the selected genes,
each of which might make only very small contributions
to smoking behavior, we then applied a network-based
approach that grouped these genes by the biological func-
tions, cellular locations, and possible interactions of their
encoded proteins. All of this information has been gathered
frommultiple bioinformatics databases and from literature
andplaced into the Ingenuitydatabase. This approachoffers
additional insights at the level of biological interpretation,
insights that would have been missed by the typical SNP-
by-SNP annotation of the top 10 or 20 SNPs. Our approach
differs frommost of the current network-based approaches
(pathway analyses) that detect whether genes predeﬁned
to belong in a certain pathway are present more often
than expected by chance. Although this can give insight
into the role of these pathways in the phenotype, the disad-
vantage is that genes that are not listed a priori in a certain
pathway are excluded and therefore missed. Pathway anal-
ysis has been developed as a generic tool, implying that
protein functions in a speciﬁc cellular context, for instance
in neurons, are largely absent. The current approach is not
limited to genes that are predeﬁned as part of a certain
pathway; instead, it uses all available information about
resemblance in structure, biological function, subcellular
localization, and direct interactions of the encoded proteins
of the selected genes. The resulting connectivity diagram
showed several noteworthy groups of genes belonging to
the same functional class (see dotted boxes in Figure 2),
and these are described in more detail below.The AmerGlutamate Signaling
Figure 2 shows several genes involved in glutamate
signaling, whereby GRIN2B, GRIN2A, GRIK2 and GRM8
show the most signiﬁcant and/or consistent associations.
Both GRIN2A and GRIN2B genes code for a subunit of
the NMDA receptor (a subgroup of the ionotropic gluta-
mate receptors). GRIN2B has not been detected yet in
human studies but its expression is associated with nico-
tine use in rats. Levels of GRIN2B were signiﬁcantly
increased in rat brains after chronic nicotine self-adminis-
tration.31 GRIN2A was detected in a recent GWAS of
smoking cessation.15 GRIK2 belongs to the kainate recep-
tors (another subgroup of ionotropic glutamate receptors)
and was also identiﬁed in a GWA for smoking cessation.15
The metabotropic receptor GRM8 has not been associated
with smoking behavior or addiction vulnerability in
previous studies although the family member GRM7 was
found both in GWAS for nicotine dependence14 and addic-
tion vulnerability19 as well as in the present study. These
ﬁndings suggest that glutamate signaling might play an
important role in smoking behavior. Glutamatergic neuro-
transmission is involved in most aspects of normal brain
function and is affected in many neuropathologic condi-
tions, including addiction.32
Tyrosine Kinase Signaling
Results of the present study contain several genes involved
in tyrosine kinase signaling, including a strong association
for NTRK2, the receptor for brain-derived neurotrophic
factor (BDNF). The NTRK2 gene is located in a region on
chromosome 9 that showed suggestive linkage to smoking
behavior in four independent studies.8 In addition,
a family-based association analysis showed an association
with nicotine dependence in two samples.33 NTRK2 is also
signiﬁcantly regulated by nicotine at both mRNA and
protein levels in various brain regions in rats.34 Tyrosine
kinases regulate various cellular processes—for instance,
nicotinic acetylcholine receptors, which are directly
involved in the rewarding effects of smoking.35 A remark-
able ﬁnding within this group is the GRB14 gene (MIM
601524). The product of this gene belongs to a small familyFigure 2. Overview of the Selected Genes and Their Subcellular Localization, Function, and Interactions
Genes were selected according to the procedure depicted in Figure 1. Ingenuity pathway analysis was used for visualizing interactions
between proteins (encoded by the selected genes) in a network graph. The Ingenuity database contains a large amount of information
about structure, biological function, and subcellular localization of the proteins, as well as direct protein-protein interactions. The
proteins encoding the selected genes are represented as nodes. Nodes are displayed in various shapes that represent the functional class
of the gene product (see symbol legend at bottom side of figure). The location of the nodes is based on the subcellular location of the
gene products: extracellular, plasma membrane, cytoplasme, nucleus, or unkown localization.
Small symbols indicate genes with lowest SNP 0.005 < p value > 0.0001 in the discovery sample; large symbols indicate genes with
p value < 0.0001. Depicted in green are the genes for SI; in blue are those for CS; in orange are those that are associated with both
SI and CS. The light-gray-colored genes had empirical p values > 0.10, and for the dark gray symbols, 0.05 < empirical p < 0.10.
The lines between symbols indicate direct connectivity between nodes, such as protein-protein interaction and/or functional regulatory
relationships.
Nodes were manually reorganized with the ‘‘pathway designer’’ for grouping the proteins with related structure or function. Groups of
genes belonging to the same functional class are enveloped with dotted lines. Of particular interest are groups of genes such as those
encoding glutamate receptors, tyrosine kinase receptors, transporters, or cell-adhesion molecules (see text).ican Journal of Human Genetics 84, 367–379, March 13, 2009 375
ofadaptorproteinsthatareknownto interactwithanumber
of receptor tyrosine kinases and signaling molecules. The
protein probably has an inhibitory effect on receptor tyro-
sine kinase signaling and on insulin receptor signaling.
This genemight play a role in signaling pathways that regu-
late growth and metabolism and has not been associated
with smokingor addiction vulnerability inprevious studies.
Transporters
Previous research suggested that the serotonin transporter
(SLC6A4) and the dopamine transporter (SLC6A3) play an
important role in smoking behavior.36 The current study
didnotdetect those two transporters but foundassociations
between smoking and several other transporter genes (see
dotted box in Figure 2). In particular, SLC1A2, a high-
afﬁnity glutamate transporter, is of interest. The SLC1A2
gene codes for a membrane-bound protein that is the prin-
cipal transporter that clears glutamate from the extracel-
lular synaptic space in the central nervous system, and as
such, it ﬁts into the glutamate signaling that seems to
play an important role in smoking behavior, as described
above. The gene was associated with CS, not with SI (both
in the discovery sample and in the Rotterdam sample).
The genewas also associatedwith successful smoking cessa-
tion in a previous GWA study.15 Themost signiﬁcant trans-
porter gene, SLC9A9, encoding a sodium and hydrogen
exchanger, was not found in previous studies including
smoking phenotypes or addiction vulnerability but this
gene had the strongest overall association in a GWAS for
ADHD.37 Inattention is a predictor of SI independent of
parental smoking.38Arecent family studyshowedacosegre-
gation of smoking and ADHD, suggesting that the two
disorders are cotransmitted through families more often
than expected by chance,39 which means that it is possible
that common genes inﬂuence both traits.
Cell-Adhesion Proteins
Nine of the cell-adhesion genes in the dotted box in Figure 2
were associated at least once with smoking or addiction
vulnerability in previous studies: CDH13, CNTN4, CNTN5,
CTNNA2, CTNNA3, CTNND2, DSCAM, NRXN1, and
NRXN3.13–15,18,19,40 Axon-associated cell-adhesion mole-
culesof the immunoglobulin (Ig) superfamilyplay important
roles in the formation, maintenance, and plasticity of func-
tional neuronal networks. CNTN4 andCNTN5 aremembers
of the contactin subgroup of thesemolecules. The activity of
cadherins, which mediate homophilic cell-cell Ca(2þ)-
dependent association, depends on their anchorage to the
cytoskeleton via proteins termed catenins, of which
CTNNA2, CTNNA3, CTNND2 are representatives. Alpha-
neurexins NRXN1 and NRXN3 organize presynaptic termi-
nals by functionally coupling calcium channels to the
presynaptic machinery. We also identiﬁed these calcium
channels (see dotted box in Figure 2), but they were not
signiﬁcant in our analyses after permutation analysis.
Most of those cell-adhesion molecules are large and
therefore might have a higher chance of being a false posi-376 The American Journal of Human Genetics 84, 367–379, March 1tive. This was dealt with rather well by the permutation
tests, and most genes in this group are grayscaled in the
graphical depiction of the gene networks in Figure 2, indi-
cating that they did not pass the permutation test.
However, a remaining signiﬁcant result within this group
of genes was found for CDH23. SNPs within this gene
also showed strong associations with extraversion,41
a strong correlate of smoking.
Opioid System
In the discovery sample, the only gene that had a p value
smaller than 10-4 and did not pass the permutation test
is OPCML, which encodes an opioid-binding protein. It
showed an association with SI and CS both in the
discovery sample and in four of the six replication studies,
but the empirical p value was 0.10. The gene is large: there
were 345 measured SNPs in the discovery set. The encoded
protein (NCBI) is localized in the plasma membrane and
might have an accessory role in opioid receptor function.
In addition, OPRM1 is associated with SI (both in the
discovery sample and in the Rotterdam sample) and was
associated with nicotine reinforcement in a candidate-
gene study.42 Several lines of evidence, from both animal
studies and studies in humans, suggest interactions
between the nicotinic and opioid receptor systems, partic-
ularly in the context of nicotine addiction.43 Although this
indicates that OPCML is a likely candidate for smoking
behavior or addiction vulnerability, because of the empir-
ical p value in the present study, we must be cautious
with this conclusion.
Known Candidate Genes for Smoking Behavior
In the past, a variety of plausible candidate genes have
been examined for associations with smoking behavior.
The vast majority of these studies have focused on varia-
tion in genes from apparently relevant neurotransmitter
pathways, in particular dopamine and nicotinic acetylcho-
line receptor genes. Previous GWA studies reported associ-
ations between SNPs in the CHRNA3-A5-B4 complex16,17
or in CHRNB3 genes13 and smoking behavior. Several
candidate-gene studies reported SNPs in the CHRNA3-A5-
B4 complex to be associated with smoking behavior and
smoking-related disease.44,45 These results suggest that
nicotinic acetylcholine receptor genes might play an
important role once smoking is initiated, but we could
not conﬁrm this in the present study. Evidence for a role
of genetic variation in dopaminergic neurotransmission
in smoking behavior is surprisingly absent. Dopaminergic
genes did not dominate the top signals in either the recent
GWAs for smoking behavior or the present study. Animal
studies have shown that besides the mesocorticolimbic
dopaminergic system, many other neurochemical systems
are involved in nicotine reinforcement by interacting with
the midbrain dopamine system. These systems include
the glutamergic, GABA-ergic, and opioid systems.46 The
present study shows a noteworthy association between
smoking and genes involved in glutamate signaling. This3, 2009
indicates that the role of the glutamate-signaling pathway
has been unjustly neglected in favor of the dopaminergic-
signaling pathway and deserves more attention in future
genetic research on smoking behavior.
Related Psychiatric Traits
Several psychiatricdisorders, suchas schizophrenia,ADHD,
autism, and substance abuse, are correlated with smoking
behavior, and smoking has a tentative role as self-medica-
tion in these subjects. Anumber of the genes thatwere iden-
tiﬁed in the present study as associated with smoking
behavior are also involved in those disorders. Glutamate
genes, including GRIN2A, GRIN2B, and GRM8, have been
associated with schizophrenia, ADHD, autism, alcohol
use, and heroin addiction.47–51 NTRK2 was associated
with ADHD,52 and MSRA, coding for a metabolic enzyme,
was recently suggested as a novel schizophrenia gene.53
These overlapping results indicate that part of the genes
inﬂuencing smoking behavior reﬂect the genetic suscepti-
bility to these psychiatric disorders.
Limitations of the Study
Our network analysis provides only one possible view of
complex genetic determinants of disease vulnerability.
The approach used here was, by deﬁnition, entirely gene-
centric. This ignores the information in the signiﬁcant
SNPs or SNP clusters that were not located in a gene. Yet,
many of these SNPs could prove to be relevant with
increasedunderstandingof the functional role of intergenic
regions. The SNP with the lowest p value (rs6484176, p ¼
8.8 3 107 for CS), for instance, is located at a distance of
around570kb fromTMEM16C.BDNF, whichhas beenasso-
ciated with smoking behavior in previous studies,54,55 is
located around1900kb from this SNP. Seven linkage studies
have reported a peak, ranging between 2.1 cM and 76.1 cM,
on chromosome 11,8 and in the present study, four
different SNPs with p values smaller than 1 3 104 are de-
tected in this region (6,281,210–25,744,207 bp). Another
example is the SNP cluster on chromosome 7 (see Results
section); the cluster is not located in a gene, but a linkage
study of smoking quantity detected a peak in the same
region (57.8–69.6 cM). These examples suggest that inter-
genic regions that are not picked up by the pathway-anal-
ysis approach, such as the ones on chromosomes 7 and
11, might still play an important role in smoking behavior.
A second limitation is that the discovery sample was
originally selected for a case-control study of major depres-
sion, a trait that is correlated with smoking behavior. The
association between smoking and depression could arise
in part from genetic factors that predispose one to both
smoking and depression.56 The replication samples and
the existing literature did not have this selection on
depression or on other psychiatric disorders. Therefore,
the signiﬁcant genes identiﬁed and discussed in the
present study are primarily involved in smoking behavior,
although we cannot exclude additional involvement in
depression.The AmeConclusions
The present study provides evidence that genes inﬂu-
encing smoking behavior tend to code for proteins that
have similar biological functions. Of particular interest
were the proteins involved in glutamate signaling (e.g..
GRIN2B, GRIK2, GRM8, SLC1A2), transporters (e.g.,
SLC9A9), proteins involved in tyrosine kinase receptor
signaling (e.g., NTRK2, GRB14), and cell-adhesion proteins
(e.g., CDH23). We conclude that a network-based GWA
approach is useful for identifying genes inﬂuencing
smoking behavior and that this approach could be useful
for other phenotypes, as well.
Supplemental Data
Supplemental Data include one table and are available with this
article online at http://www.ajhg.org/.
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